Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,958 total articles
Old National Bancorp announced a strategic realignment of its commercial banking leadership, including the hiring of Chris Doyle as President of Commercial Banking and the promotion of John C. Thurston to President of Corporate Banking. Additional leadership adjustments were made in Treasury Management and service delivery to enhance client service…
Calavo Growers, Inc., a leader in fresh produce sourcing and processing, declared a quarterly cash dividend of $0.20 per share. The company amended the dividend record date to April 24, 2026, while maintaining the payment date of April 29, 2026. This adjustment complies with Nasdaq's notice requirements without changing dividend value or payment ti…
Allogene Therapeutics announced encouraging interim futility analysis results from its Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel), an allogeneic CAR T therapy, in first-line consolidation for large B-cell lymphoma (LBCL). The cema-cel arm showed a 58.3% minimal residual disease (MRD) clearance rate versus 16.7% in the ob…
BullFrog AI Holdings announced a significant commercial feasibility agreement with a top 5 global pharmaceutical company to use its AI platform bfLEAP® to identify novel drug targets in major depressive disorder. The company also strengthened its balance sheet with recent financings to support operations into late 2027 and is advancing multiple dis…
ASP Isotopes Inc. presents a comprehensive business update highlighting operational milestones across its nuclear medicine, electronics, and nuclear energy platforms. The company anticipates first commercial shipments of several enriched isotopes including Silicon-28, Carbon-14, and Ytterbium-176 in 2026, expects to reach helium production capacity…
Palvella Therapeutics, a clinical-stage biopharmaceutical company specializing in rare skin diseases and vascular malformations, announced the appointment of John D. Doux, M.D., M.B.A., a recognized dermatologist and investor in rare skin disease therapies, to its Board of Directors. Dr. Doux's deep medical experience and previous advocacy for inno…
PMGC Holdings Inc.'s subsidiary NorthStrive Biosciences announces the successful transfer of the EL-32 Working Cell Bank to a U.S.-based fermentation facility, initiating manufacturing optimization aimed at scalable and cost-effective production. EL-32 is an engineered probiotic therapeutic targeting muscle preservation by modulating myostatin and …
Hillman Solutions Corp. announced the acquisition of Delaney Hardware, a U.S.-based door hardware supplier serving residential, multifamily, and commercial construction markets. This acquisition strategically expands Hillman's pro distribution categories by adding door hardware products and broadens its builder's hardware inventory. The company exp…
3D Systems has unveiled its next-generation SLA 825 Dual stereolithography system offering 22% larger build volume and up to 25% faster print speeds to enhance production throughput. Alongside, it launched AddiTrak™, an advanced on-premises factory software platform for real-time fleet monitoring and process control. These innovations aim to accele…
Oil-Dri Corporation of America (NYSE: ODC) was named a 2026 USA TODAY Top Workplaces winner, an accolade based on confidential employee feedback showcasing the company's commitment to a collaborative and supportive work environment. This recognition highlights Oil-Dri's people-first culture, emphasizing transparency, employee engagement, and opport…
Akebia Therapeutics has dosed the first participants in a Phase 1 clinical trial of AKB-9090, an internally developed HIF-PH inhibitor aimed at treating cardiac surgery-associated acute kidney injury (AKI). The randomized, double-blind, placebo-controlled study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adul…
Revolution Medicines announced positive topline results from the RASolute 302 Phase 3 clinical trial evaluating daraxonrasib, an oral targeted therapy, in previously treated metastatic pancreatic ductal adenocarcinoma patients. The trial met all primary and key secondary endpoints, showing a significant improvement in progression-free survival and …
CVRx, Inc. announced preliminary unaudited financial results for Q1 2026, reporting approximately 20% revenue growth year over year to $14.7-$14.8 million. The company noted improvements in Medicare Advantage prior authorization approval rates following implementation of Category I CPT codes, and activated the first site in the BENEFIT-HF clinical …
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company specializing in local, controlled drug delivery using its Diffusphere™ technology, announced participation in upcoming investor conferences in New York and Toronto. The company is advancing clinical trials for its lead products, including EP-104GI for eosinophilic esophagitis and…
Enphase Energy announced increased shipments of advanced commercial microinverters manufactured in the U.S., including the new IQ9N-3P model designed for three-phase commercial solar installations. These products comply with domestic content rules to qualify for federal tax credits and are being adopted for commercial and repowering solar projects …
Elite Express Holding Inc. reported first quarter 2026 financial results showing a 16.3% year-over-year revenue increase to $805,298 and a 46.3% reduction in net loss to $110,104. Improvements were driven by increased delivery volumes, better route and fleet management, and labor efficiency. The renewal of its ISP agreement with FedEx contributed t…
Copa Holdings announced a significant increase in passenger traffic for March 2026, with available seat miles up 14.8% and revenue passenger miles up 15.3% compared to March 2025. The company also achieved a higher load factor of 86.7%.
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments for mental health disorders, will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company continues to build awareness for its FDA-cleared Deep Transcranial Magnetic Stimulation (Deep TMS) technology, which treats major depressive disorder, O…
Lamar Advertising Company announced that it will release its first quarter ended March 31, 2026 operating results before the market opens on May 7, 2026. The company will host a conference call on the same day to discuss the results and company operations.
Par Pacific Holdings, Inc. announced it will release its Q1 2026 earnings after NYSE closes on May 5, 2026, followed by a conference call on May 6, 2026. The company operates refining, energy infrastructure, retail fuel brands, and a stake in natural gas production.
HighPeak Energy, Inc., an independent oil and natural gas exploration company focused in the Midland Basin, announced its participation in the Water Tower Research Insights Conference with virtual presentations by CEO Michael Hollis and EVP Ryan Hightower. The event aims to enhance investor communications and engagement, featuring companies from va…
VisionWave Holdings, a Nasdaq-listed defense technology company, has acquired the xClibre AI video intelligence intellectual property valued at approximately $60 million. The acquisition enhances VisionWave's sensing architecture by adding AI-driven video analytics to their existing RF-based detection systems. The company plans to integrate xClibre…
Orrstown Financial Services, Inc. announced that it will release its first quarter 2026 earnings report after market close on April 21, 2026. The company will hold a conference call and webcast on April 22, 2026, for management to review the quarterly results with investors and analysts.
Septerna, Inc., a clinical-stage biotech company focused on GPCR drug discovery, has initiated a Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist designed to treat hypoparathyroidism. The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, with data expected by late 2026 or e…
Bitcoin Depot announced the hiring of Tony Gagliardi as Chief Compliance Officer to lead and enhance the company's compliance framework amid evolving regulatory requirements. Gagliardi brings over 15 years of experience across financial services and digital assets, overseeing anti-money laundering, Know-Your-Customer programs, and state-level regul…
